Suzuki, Shiho https://orcid.org/0009-0007-7430-2078
Ishii, Ryotaro https://orcid.org/0000-0002-6976-1081
Danno, Daisuke https://orcid.org/0000-0003-3737-4754
Takizawa, Tsubasa https://orcid.org/0000-0003-2605-7200
Hamakawa, Masayuki https://orcid.org/0000-0003-1823-8394
Tanizawa, Yoshinori https://orcid.org/0000-0002-5014-2483
Osaga, Satoshi https://orcid.org/0000-0003-4459-2469
Sasaki, Nao https://orcid.org/0009-0003-2252-6724
Hashimoto, Chie https://orcid.org/0009-0008-0227-8993
Komori, Mika https://orcid.org/0000-0003-1887-1296
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 26 June 2025
Accepted: 29 September 2025
First Online: 28 October 2025
Declarations
:
: Shiho Suzuki received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Ryotaro Ishii received consulting fees from Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Daisuke Danno serves on the advisory boards of Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Pfizer Japan Inc. and received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Tsubasa Takizawa is a consultant/adviser and/or serves on an advisory board for Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Eisai Co., Ltd., Sawai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., and Santen Pharmaceutical, a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura & Co., outside the submitted work. Masayuki Hamakawa is an employee of Social Survey Research Information Co., Ltd. Data collection and statistical analyses in this study were performed by Social Survey Research Information Co., Ltd. and sponsored by Eli Lilly Japan K.K. Yoshinori Tanizawa, Satoshi Osaga, Nao Sasaki, Chie Hashimoto, and Mika Komori are employees of Eli Lilly Japan K.K. and may own stock/stock options of Eli Lilly and Company.
: The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on April 19, 2023. This study was conducted in accordance with ethical principles originating from the Declaration of Helsinki, and that were consistent with Good Pharmacoepidemiology Practices. All survey respondents provided electronic informed consent and agreed to participate in the study. All data were anonymized before analysis.